Development of novel gallium-68 bisphosphonate for imaging bone metastases in prostate cancer
Ended Cooperative Agreement Awarded Last action
- Award ID
- R43CA221580
- Recipient
-
Five Eleven Pharma Inc. UEI PJUGJJT3FLM5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $225,000
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $225,000 |
Quick answers
Who received award R43CA221580?
R43CA221580 was awarded to Five Eleven Pharma Inc. by National Cancer Institute (National Institutes of Health) on August 1, 2017.
How much is award R43CA221580 worth?
$225,000 has been obligated on R43CA221580.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award